KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Adaptive Biotechnologies (ADPT) Gross Profit (2018 - 2025)

Adaptive Biotechnologies' Gross Profit history spans 8 years, with the latest figure at $70.4 million for Q4 2025.

  • For Q4 2025, Gross Profit rose 109.05% year-over-year to $70.4 million; the TTM value through Dec 2025 reached $205.6 million, up 92.39%, while the annual FY2025 figure was $205.6 million, 92.39% up from the prior year.
  • Gross Profit for Q4 2025 was $70.4 million at Adaptive Biotechnologies, up from $58.9 million in the prior quarter.
  • Across five years, Gross Profit topped out at $70.4 million in Q4 2025 and bottomed at -$16.2 million in Q2 2023.
  • The 5-year median for Gross Profit is $28.0 million (2022), against an average of $30.4 million.
  • The largest annual shift saw Gross Profit crashed 137.31% in 2023 before it soared 247.62% in 2024.
  • A 5-year view of Gross Profit shows it stood at $57.4 million in 2021, then dropped by 21.23% to $45.2 million in 2022, then crashed by 47.19% to $23.9 million in 2023, then surged by 41.06% to $33.7 million in 2024, then skyrocketed by 109.05% to $70.4 million in 2025.
  • Per Business Quant, the three most recent readings for ADPT's Gross Profit are $70.4 million (Q4 2025), $58.9 million (Q3 2025), and $40.9 million (Q2 2025).